Prostate Cancer Clinical Trials in Maryland

Showing 21-40 of 384 trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Cervical CancerBreast CancerColon Cancer+4 more

Orano Med LLC48 participantsStarted Dec 2022

Chicago, Illinois, United States • Lexington, Kentucky, United States • Glen Burnie, Maryland, United States +1 more locations

Active Not RecruitingPhase 313 miles

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.

Metastatic Castrate-sensitive Prostate Cancer

Janssen Research & Development, LLC420 participantsStarted Aug 2023

Homewood, Alabama, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +90 more locations

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Prostate Cancer Trials in Other Cities

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

Other Conditions in Maryland